Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects

Acta Diabetologica

Volumn 41, Issue 4, 2004, Pages 146-153

  Tankova, T ^a   Dakovska, G ^a   Lazarova, M ^a   Dakovska, L ^a   Kirilov, G ^a   Koev, D ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Insulin resistance; Insulin secretion; Obesity; Sibutramine; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; INSULIN; LIPID; SIBUTRAMINE;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; EXERCISE; FEMALE; GLYCEMIC INDEX; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

ADIPOSE TISSUE; ADULT; APPETITE DEPRESSANTS; BLOOD GLUCOSE; BODY WEIGHT; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY; WAIST-HIP RATIO;

EID: 12944308320     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00592-004-0158-7     Document Type: Article

References (38)

1. - (2000) Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series, no. 894. WHO, Geneva
2. Van Gaal LF, Peiffer FW (2001) The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes 25[Suppl 4]:S24-S28
3. Eckel RH, Krauss RM (1998) American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 97:2099-2100
4. Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obes 16:397-415
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-402
7. The Trials of Hypertension Prevention Collaborative Research Group (1997) Effects of weight loss and sodium reduction on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 157:657-667
8. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
9. Lehto S, Ronnemaa T, Pyorala K, Laakso M (2000) Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 43:148-155
10. Hauner H (2001) Current pharmacological approaches to the treatment of obesity, Int J Obes Relat Metab Disord 25[Suppl 1]:S102-S106
11. Lean MEJ (2001) How does sibutramine work? Int J Obes 25[Suppl 4]:S8-S11
12. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF (2000) Effect of sibutra mine on weight maintenance after weight loss: a randomised trial. STORM Study Group, Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119-2125
13. Serrano-Rios M, Melchionda N, Moreno-Carretero E (2002) Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 19:119-124
14. Smith IG (2001) Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50:505-512
15. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J (2000) Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2:105-112
16. Alberti KGMM, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet Med 15:539-553
17. - (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
18. Kostner G (1976) Enzymatic determination of cholesterol in high density lipoprotein fractions prepared by polyanion precipitation. Clin Chem 22:695-698
19. Gianani R, Pugliese A, Bonner-Weir S, Shiffrin AJ, Soeldner JS, Erlich H, Awdeh Z, Alper CA, Jackson RA, Eisenbarth GS (1992) Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 41:347-353
20. Bingley PJ, Colman P, Eisenbarth GS, Jackson RA, McCulloch DK, Riley WJ, Gale EA (1992) Standardization of IVGTT to predict IDDM. Diabetes Care 10:1313-1316
21. Vardi P, Crisa L, Jackson RA (1991) Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 34:93-102
22. Tallaride RJ, Murray PB (1981) Manual of pharmacologic calculations. Springer, Berlin Heidelberg New York
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
24. - (1985) Energy and protein requirement. Report of a Joint FAO/WHO/UNU Expert Consultation. Technical Report Series no. 724. WHO, Geneva
25. McNulty SJ, Ur E, Williams G, Multicenter Sibutramine Study Group (2003) A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26(1):125-131
26. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N (2001) Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 24:1957-1960
27. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP (2000) Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2:175-187
28. Stunkard AJ (1996) Current views on obesity. Am J Med 100:230-236
29. Pi-Sunyer FX (1993) Medical hazards of obesity. Ann Intern Med 119:655-660
30. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
31. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB (1999) Sibutramine produces dose-related weight loss. Obes Res 7:189-198
32. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD (2000) Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: a one-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160:2185-2191
33. Grodsky GM (1997) An update on implications of phasic insulin secretion. In: Pickup J, Williams G (eds) Textbook of diabetes, vol. 1. Blackwell Scientific, Oxford, pp 421-430
34. Wallum BJ, Kahn SE, McCulloch DK (1992) Insulin secretion in the normal and diabetic human. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds) International textbook of diabetes mellitus. John Wiley, Chichester, New York, Weinheim, Brisbane, Singapore, Toronto, pp 285-301
35. DeFronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM: a precarious balance between insulin action and insulin secretion. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P (eds) International textbook of diabetes mellitus. John Wiley, Weinheim, Brisbane, Singapore, Toronto, pp 569-633
36. Porte DJ (1991) Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 40:166-180
37. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63
38. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K (2002) Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16:5-11